{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:58:38Z","timestamp":1790539118023,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.farma.2026.07.009","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:30:21Z","timestamp":1790220621000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases"],"prefix":"10.1016","author":[{"given":"Juan Carlos","family":"del R\u00edo-Valencia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Tamayo-Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Diego","family":"Paradas-Palomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Mora-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"L\u00f3pez-Escola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.farma.2026.07.009_bb0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.farma.2026.07.009_bb0010","first-page":"256","article-title":"Incidence proportions of brain metastases","volume":"6","author":"Barnholtz-Sloan","year":"2004","journal-title":"Neuro-Oncology"},{"issue":"11","key":"10.1016\/j.farma.2026.07.009_bb0015","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.farma.2026.07.009_bb0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"19","key":"10.1016\/j.farma.2026.07.009_bb0025","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive NSCLC (KEYNOTE-024)","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"10183","key":"10.1016\/j.farma.2026.07.009_bb0030","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated PD-L1\u2013expressing NSCLC (KEYNOTE-042)","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.farma.2026.07.009_bb0035","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"issue":"28","key":"10.1016\/j.farma.2026.07.009_bb0040","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of PD-1\/PD-L1 blockade in advanced NSCLC","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.farma.2026.07.009_bb0045","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jtho.2019.02.009","article-title":"Survival of NSCLC patients with leptomeningeal metastases treated with immune checkpoint inhibitors","volume":"14","author":"Hendriks","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.farma.2026.07.009_bb0050","first-page":"e363","article-title":"Intracranial response to immune checkpoint inhibitors in NSCLC patients with brain metastases","volume":"19","author":"Dudnik","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.farma.2026.07.009_bb0055","first-page":"22","article-title":"Clinical outcomes with immune checkpoint inhibitors in NSCLC patients with brain metastases","volume":"129","author":"Metro","year":"2019","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.farma.2026.07.009_bb0060","first-page":"631","article-title":"Outcome of NSCLC patients with brain metastases treated with checkpoint inhibitors","volume":"30","author":"Hendriks","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.farma.2026.07.009_bb0065","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1080\/21645515.2020.1823779","article-title":"Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis","volume":"17","author":"Huang","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.farma.2026.07.009_bb0070","first-page":"29","article-title":"Liver metastases as a poor prognostic factor in non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"115","author":"Tamiya","year":"2018","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.farma.2026.07.009_bb0075","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic radiotherapy vs pembrolizumab alone on tumor response in patients with advanced NSCLC: the PEMBRO-RT randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:45:35Z","timestamp":1790538335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326001789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":15,"alternative-id":["S1130634326001789"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.07.009","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}